ReviewAerospace medicine and human performance2017
Novel Indications for Commonly Used Medications as Radiation Protectants in Spaceflight.
Review in Aerospace medicine and human performance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Low-dose X-ray radiation induces an adaptive response: A potential countermeasure to galactic cosmic radiation exposure.Experimental physiology · 2026Article
- Leveraging bioinformatics approaches for drug repositioning in space radiation protection.PloS one · 2026Article
- Concept and preliminary structural analysis of a crater-covering dome for future lunar habitats.Scientific reports · 2025Article
- Pharmacological Innovations in Space: Challenges and Future Perspectives.Pharmaceutical research · 2024Review
- Review
- Evaluation of deep space exploration risks and mitigations against radiation and microgravity.Frontiers in nuclear medicine · 2023Review
- Inter-agency perspective: Translating advances in biomarker discovery and medical countermeasures development between terrestrial and space radiation environments.Life sciences in space research · 2022Article
- Neuroprotective agents effective against radiation damage of central nervous system.Neural regeneration research · 2022Review
- Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry.Antioxidants (Basel, Switzerland) · 2022Review
- Myocardial Disease and Long-Distance Space Travel: Solving the Radiation Problem.Frontiers in cardiovascular medicine · 2021Review
- The Future of Personalized Medicine in Space: From Observations to Countermeasures.Frontiers in bioengineering and biotechnology · 2021Review
- Radioprotection and Radiomitigation: From the Bench to Clinical Practice.Biomedicines · 2020Review
- Clinical efficacy of acetylcysteine combined with tetrandrine tablets on patients with silicosis and its effect on exercise tolerance and pulmonary function.Experimental and therapeutic medicine · 2020Article
- Medicinal Thiols: Current Status and New Perspectives.Mini reviews in medicinal chemistry · 2020Review
- Ionizing Radiation induction of cholesterol biosynthesis in Lung tissue.Scientific reports · 2019Article
- Renin angiotensin system and its role in biomarkers and treatment in gliomas.Journal of neuro-oncology · 2018Review
- Space medicine: Hunting for pharmacologist's guide in dealing with drugs in microgravity.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIn the space environment, the traditional radioprotective principles of time, distance, and shielding become difficult to implement. Additionally, the complex radiation environment inherent in space, the chronic exposure timeframe, and the presence of numerous confounding variables complicate the process of creating appropriate risk models for astronaut exposure. Pharmaceutical options hold tremendous promise to attenuate acute and late effects of radiation exposure in the astronaut population. Pharmaceuticals currently approved for other indications may also offer radiation protection, modulation, or mitigation properties along with a well-established safety profile. Currently there are only three agents which have been clinically approved to be employed for radiation exposure, and these only for very narrow indications. This review identifies a number of agents currently approved by the U.S. Food and Drug Administration (FDA) which could warrant further investigation for use in astronauts. Specifically, we examine preclinical and clinical evidence for statins, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), metformin, calcium channel blockers, β adrenergic receptor blockers, fingolimod, N-acetylcysteine, and pentoxifylline as potential radiation countermeasures.McLaughlin MF, Donoviel DB, Jones JA. Novel indications for commonly used medications as radiation protectants in spaceflight. Aerosp Med Hum Perform. 2017; 88(7):665-676.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.